Arabic Arabic English English French French German German
dark

Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nonviral Gene Therapies for Up to Two Rare Liver Diseases

Genevant Sciences announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company Limited for the development and commercialization of novel nonviral gene therapies to treat up to two undisclosed rare liver diseases. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member

Next Post

LUNGevity Foundation and Partner Hamoui Family Foundation Issue 2022 Request for Applications for RET-Positive Clinical Lung Cancer Research

Related Posts
Total
0
Share